Will PCT report FY2026 revenue exceeding $30M?
Current Prediction
Why This Question Matters
Revenue trajectory directly tests whether the FRAGILE revenue durability assessment is too pessimistic or accurate. $30M for FY2026 would represent ~3.6x growth from $8.4M, requiring meaningful Ironton ramp success. Achieving this would narrow the narrative-reality gap and suggest the technology scales. Falling short would confirm the single-facility risk and raise questions about whether $8.4M was an anomaly rather than a foundation.
Prediction Distribution
Individual Predictions(9 runs)
PCT reported $8.4M in FY2025, its first year of revenue. $30M for FY2026 requires 3.6x growth, implying ~$7.5M per quarter. This is nearly the entire FY2025 revenue every quarter. Ironton required a turnaround that will consume part of the production calendar. The committee assessed UNIT_ECONOMICS as BROKEN and REVENUE_DURABILITY as FRAGILE. Single-facility risk means any disruption eliminates all revenue. Customer base is early-stage. Even assuming a successful turnaround, ramping from ~$2M/quarter average to $7.5M/quarter consistently is extremely demanding for a facility that hasn't demonstrated stable production.
The math is demanding. FY2025 averaged ~$2.1M/quarter. Even if the turnaround doubles throughput (optimistic), we get ~$4.2M/quarter average for FY2026, totaling ~$16.8M — well short of $30M. To reach $30M, throughput would need to approximately quadruple and sustain that level for most of the year. Chemical processing facilities rarely achieve 4x throughput improvement in a single year, especially when starting from initial production with demonstrated scaling issues. The BROKEN unit economics assessment reinforces this skepticism.
I'll consider the bull case: if the turnaround is highly successful and addresses the primary bottleneck, Ironton could potentially reach a much higher utilization rate in H2 2026. Chemical processing economics are nonlinear — small changes in utilization can produce large changes in output. If Ironton was running at 10-15% utilization, a turnaround that brings it to 40-50% could produce $5-8M/quarter. But this requires the turnaround solving the core issue (not just patching), immediate ramp after downtime, and stable production for 3+ quarters. The conjunction of these favorable outcomes is unlikely given the analysis findings.
FY2025 was the first year of revenue, and year-2 chemical processing ramps can be significant. The turnaround is designed to address the specific throughput constraints. If successful, H2 2026 could see meaningfully higher production. The customer pipeline exists (management says only small percentage needed to fill capacity). Regulatory mandates create pull demand. However, $30M requires approximately $7.5M/quarter average, which is a large jump from $2.1M. The most likely scenario is meaningful improvement that falls short of $30M — perhaps $15-20M for FY2026.
The $30M threshold is specifically demanding. Even if we assume Q1 2026 is a turnaround quarter (low revenue), Q2-Q4 would need to average $9-10M each to compensate. That's essentially 4-5x the FY2025 quarterly run rate, sustained for three consecutive quarters. In a facility that has never demonstrated stable production at any level, this is extremely optimistic. The FRAGILE revenue assessment and single-facility concentration amplify the risk. Revenue of $15-20M is more plausible but $30M requires near-perfect execution.
I'll assign the base case as ~$15-18M FY2026 revenue (a significant improvement but short of $30M). The right tail that reaches $30M requires: (1) turnaround completed by Q1 end, (2) immediate ramp to high utilization, (3) no new disruptions, (4) customer demand materializing. Each individually is plausible but the conjunction is demanding. I estimate ~20% probability that everything aligns for the $30M threshold, with the base case being meaningful improvement that falls short.
3.6x growth from $8.4M base. Single facility that needed first-year turnaround. No demonstrated stable production. $30M requires near-perfect execution for the full year. Very demanding target given BROKEN unit economics and FRAGILE revenue.
Year-2 ramps in chemical processing can be significant. If turnaround solves the core issue, revenue could accelerate materially. But $30M is 3.6x growth — a very high bar. Most likely revenue is $12-18M range.
The turnaround takes production offline, then must ramp back up, then maintain at higher levels. Full year includes downtime quarter. $30M from $8.4M with a facility that has never demonstrated stable production at any level is extremely ambitious.
Resolution Criteria
Resolves YES if PCT's 10-K for FY2026 (filed Q1 2027) reports total revenue of $30M or more. Resolves NO if total revenue is below $30M.
Resolution Source
PCT 10-K for fiscal year ending December 31, 2026
Source Trigger
Revenue trajectory — revenue durability depends on Ironton ramp and virgin PP premium
Full multi-lens equity analysis